New Rules of Global Pharma: When Everything Changes at Once

The pharmaceutical industry is operating under fundamentally different rules than five years ago. Medicines are now treated as strategic national assets while still governed by cost-minimization economics. Manufacturing capacity has become selective rather than universal, with execution quality trumping price. Geopolitical tensions have transformed from background noise into active investment criteria, forcing companies to rebuild supply chains around resilience rather than efficiency.

Key Points:

- Strategic assets, outdated economics -Governments frame medicines as critical infrastructure while procurement systems still reward lowest cost over supply security

- Selective capacity allocation - CDMOs prioritize projects based on technical expertise and regulatory track records, not just available slots

- Geopolitical risk as business criteria -Trade tensions and regulatory fragmentation now drive capital allocation decisions and manufacturing location strategies